Clareo Health | A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Glaxo Wellcome
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Co-existing Condition:
Patients with the following are excluded:
Past or present renal disease.
Significant bone marrow suppression.
Blood transfusion within the past month.
Liver dysfunction.
Evidence of an underlying, severe infection.
Evidence of an active life-threatening opportunistic infection at study entry.
Severe malabsorption (patients with recent significant weight loss must have a serum carotene level of \> 75 IU/ml).
Evidence of nervous system dysfunction being caused by factors other than HIV infection, particularly by cerebral toxoplasmosis, lymphoma, cryptococcal meningitis, chronic alcohol abuse, lead poisoning, cytomegalovirus (CMV) infection (patients with retinal CMV infection or other evidence of CMV dementia), syphilis, or progressive multifocal leukoencephalopathy.
Other known causes of nerve or muscle disease.
Hypersensitivity to zidovudine (AZT).
Lymphoma or other tumor requiring cytotoxic chemotherapy.
Concurrent Treatment:
Allowed:
Electron beam therapy to an area of less than 100 cm2.
Patients with the following are excluded:
Past or present renal disease.
Significant bone marrow suppression.
Blood transfusion within the past month.
Liver dysfunction.
Evidence of an underlying, severe infection.
Evidence of an active life-threatening opportunistic infection at study entry.
Severe malabsorption (patients with recent significant weight loss must have a serum carotene level of \> 75 IU/ml).
Evidence of nervous system dysfunction being caused by factors other than HIV infection, particularly by cerebral toxoplasmosis, lymphoma, cryptococcal meningitis, chronic alcohol abuse, lead poisoning, cytomegalovirus (CMV) infection (patients with retinal CMV infection or other evidence of CMV dementia), syphilis, or progressive multifocal leukoencephalopathy.
Other known causes of nerve or muscle disease.
Hypersensitivity to zidovudine (AZT).
Lymphoma or other tumor requiring cytotoxic chemotherapy.
Patients with AIDS (CDC surveillance definition) or AIDS related complex (ARC).
All patients must have either:
Dementia as defined by a progressive cognitive impairment in the absence of altered consciousness that is thought to be causally related to HIV infection. Patients in this study will fall into the lower 20 percent (or less) of a normal sample of formal neuropsychological testing.
OR
One of the following neuromuscular diseases thought to be related to HIV infection:
